Background
INO-VATE ALL was a phase III randomized open-label trial evaluating inotuzumab ozogamicin (InO), a CD22-directed antibody-drug conjugate linked to calicheamicin, versus investigator's choice of standard intensive chemotherapy in adults with relapsed/refractory CD22-positive B-cell ALL. Salvage chemotherapy for R/R ALL achieves CR in only 20–30% with poor durability; INO-VATE tested whether CD22-targeted cytotoxic therapy could achieve deeper, more durable remissions to facilitate bridging to allogeneic SCT.
Interventions and follow up
Arm A: Investigator's choice intensive chemotherapy (FLAG; mitoxantrone + cytarabine; or high-dose cytarabine)
Arm B: Inotuzumab ozogamicin 1.8 mg/m² per cycle (dose-fractionated days 1, 8, 15) q3–4w ×up to 6 cycles → option to proceed to allogeneic SCT
Primary endpoint: CR/CRi rate and overall survival
mFollow up: 22.8 months
Arm B: Inotuzumab ozogamicin 1.8 mg/m² per cycle (dose-fractionated days 1, 8, 15) q3–4w ×up to 6 cycles → option to proceed to allogeneic SCT
Primary endpoint: CR/CRi rate and overall survival
mFollow up: 22.8 months
Results
CR/CRi: 80.7% vs 29.4% (InO vs chemo), P<.001
MRD negativity among CR/CRi: 78.4% vs 28.1% (P<.001)
mPFS: 5.0 vs 1.8 months, HR 0.45, P<.001
mOS: 7.7 vs 6.7 months, HR 0.77, 97.5% CI 0.58–1.03, P=.04 (boundary)
Bridging to allo-SCT: 41% vs 11%
MRD negativity among CR/CRi: 78.4% vs 28.1% (P<.001)
mPFS: 5.0 vs 1.8 months, HR 0.45, P<.001
mOS: 7.7 vs 6.7 months, HR 0.77, 97.5% CI 0.58–1.03, P=.04 (boundary)
Bridging to allo-SCT: 41% vs 11%
Adverse events
Hematologic (Grade ≥3, InO vs chemo): thrombocytopenia 48% vs 52%, neutropenia 49% vs 51%
Infections: Grade ≥3 infections 48% vs 52%
Hepatic / VOD: veno-occlusive disease (VOD/SOS) 11% (InO) vs 1% (chemo); post-SCT VOD 25% vs 10% — critical safety signal; elevated bilirubin 3% vs 1%
Infections: Grade ≥3 infections 48% vs 52%
Hepatic / VOD: veno-occlusive disease (VOD/SOS) 11% (InO) vs 1% (chemo); post-SCT VOD 25% vs 10% — critical safety signal; elevated bilirubin 3% vs 1%
Conclusions
Inotuzumab ozogamicin achieved a dramatically higher CR/CRi rate (81% vs 29%) and MRD-negativity rate (78% vs 28%) versus salvage chemotherapy in R/R CD22+ B-ALL, significantly improving PFS and enabling 4× more patients to bridge to allogeneic SCT, though the OS benefit was modest and complicated by clinically important post-SCT veno-occlusive disease.
Key Limitations
OS benefit marginal (HR 0.77, P=.04 crossing the pre-specified boundary), partly attributable to post-remission VOD deaths diluting the OS signal; post-SCT VOD 25% requires modified conditioning (avoid dual-alkylator regimens); patients with prior SCT at higher VOD risk; open-label design; no biomarker selection beyond CD22 expression; heterogeneous 3-regimen chemo comparator; no comparison to blinatumomab or CAR-T (tisagenlecleucel, brexucabtagene autoleucel), which now reshape the R/R B-ALL landscape.
Clinical Context
INO-VATE led to FDA approval (August 2017) and EMA approval of inotuzumab ozogamicin for R/R B-ALL in adults. The key management challenge is post-SCT VOD: patients receiving InO before allogeneic SCT require modified conditioning (avoid busulfan-based dual-alkylator regimens; consider reduced-intensity or TBI-based approaches) and ursodiol prophylaxis. In contemporary R/R ALL, InO competes with blinatumomab (TOWER) and CAR-T (tisagenlecleucel, ELIANA); its high MRD-negativity rate makes it attractive for SCT bridging, while CAR-T is favored when SCT is not planned. InO is also being studied frontline in combination with chemotherapy.